Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. - Wikidata - wikimedia - TriplyDB

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

http://www.wikidata.org/entity/Q40839780

about

MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation Cardiovascular safety of anti-diabetic drugs Delay in oral mucosal ulcer healing by aspirin is linked to the disturbances in p38 mitogen-activated protein kinase activation Phytol/Phytanic acid and insulin resistance: potential role of phytanic acid proven by docking simulation and modulation of biochemical alterations The current role of thiazolidinediones in diabetes management.The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors.Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus.The role of mitochondria in the pathophysiology of skeletal muscle insulin resistance.Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.Activation of the retinoid X receptor modulates angiotensin II-induced smooth muscle gene expression and inflammation in vascular smooth muscle cells Effect of rosiglitazone on HDL metabolism in subjects with metabolic syndrome and low HDL.PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.Peroxisome proliferator-activated receptors α and γ are linked with alcohol consumption in mice and withdrawal and dependence in humans Insulin sensitisation in the treatment of Type 2 diabetes.Broad-spectrum neuroprotection against traumatic brain injury by agonism of peroxisome proliferator-activated receptors Pharmacologic treatment of type 2 diabetic dyslipidemia.Idealized PPARγ-Based Therapies: Lessons from Bench and Bedside A phase II clinical trial to investigate the effect of pioglitazone on (18)F-FDG uptake in malignant lesions.Insulin resistance and cardiovascular disease: the role of PPARgamma activators beyond their anti-diabetic action.The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics.In Vitro and In Vivo Characterizations of Chiglitazar, a Newly Identified PPAR Pan-Agonist.Recent findings concerning thiazolidinediones in the treatment of diabetes.Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice.PPAR-gamma activation fails to provide myocardial protection in ischemia and reperfusion in pigs.Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy PPARdelta Agonism for the Treatment of Obesity and Associated Disorders: Challenges and Opportunities Selective modulation of promoter recruitment and transcriptional activity of PPARgamma.Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.Peroxisome proliferator-activated receptor ligand MCC-555 suppresses intestinal polyps in ApcMin/+ mice via extracellular signal-regulated kinase and peroxisome proliferator-activated receptor-dependent pathways Pharmacogenetics of the PPAR genes and cardiovascular disease.Beneficial effects of thiazolidinediones on diabetic nephropathy in OLETF rats The peroxisome proliferator-activated receptor-gamma agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-alpha-dependent manner in vitro and in vivo in mice.Pleiotropic effects of thiazolidinediones.PPARgamma and its ligands: therapeutic implications in cardiovascular disease.Thiazolidinediones in type 2 diabetes: a cardiology perspective.The possible role of peroxisome proliferator-activated receptor gamma in heart failure.Drug-eluting stent safety: findings from preclinical studies.PPARs as new therapeutic targets for the treatment of cerebral ischemia/reperfusion injury.PPAR agonists as therapeutics for CNS trauma and neurological diseases

P2860

Q21342745-B6726392-A26F-4E42-99A2-50716345315A Q26741082-4FBA4BA1-24B3-4114-B94E-DD89FCB3F804 Q28186400-D82F908A-F5D5-49B6-96A5-A68208338C72 Q28484781-34E9097B-9B22-4B78-AC8F-559004038929 Q30250347-A5CCD2BB-ED71-4D25-9084-25D68AA0A853 Q30486738-9E76079F-FDF4-4D8C-A6A6-71E15A0666BE Q33727061-4F9CDFDF-B524-4A46-91ED-FDC07A919185 Q33779662-514F108E-E803-4A14-9DA2-E053699E06DE Q34315432-30E83264-0E1A-4DC4-8563-189063C683C0 Q34360098-64E103D4-D7B1-4A9F-A9AE-B1D6875F603B Q34395184-40ABE875-4643-4DA3-9D36-460E1FD4D2A4 Q34509964-99DFE031-990D-40B5-BDA6-D9E26BC91CD0 Q34781949-8E51752F-73A3-4D84-84F8-CD199E2CACD4 Q35019725-8DB8EC0C-2C26-4B3B-A43D-75E129E6A6E4 Q35073317-CAE39226-B028-4D12-8A52-E6A508BFAE35 Q35603688-BC9F99F8-7F3A-4D49-BDAF-4535C5F5F800 Q35976827-3F731C14-FB04-4CA7-BA6E-E27BE4F8ED2B Q36056207-8AC4EF04-6158-4A4B-B170-D066AF2AED43 Q36094168-4D1C6DDE-549A-4F83-8D13-74F63603B6EC Q36319330-B7ACED40-31A8-421E-BE53-33174C1E7933 Q36326205-C6875BF2-A5AD-4F9F-973C-7BBC834A7156 Q36363679-344BC7EB-5A05-4B75-9BD8-704BA5DF457B Q36407304-BDC971C4-5375-455A-B252-850AC02B22DD Q36444964-F3029757-9E55-44DC-9AA7-70739D8AF18E Q36787677-D32E68E5-6361-4ECA-9B93-8F3E439C0A5F Q36935534-5C96667A-ADE6-44A3-8EDA-C4A216EBE756 Q36959065-6C7C2A2D-D667-48C1-A703-87195B107D53 Q36979694-E9CEABE9-61A2-44AA-94E7-06740DD4FE4F Q36992256-24E137DD-5324-4B20-8CD7-348ECA08E338 Q37001526-C4B4A64C-10D6-494A-828D-F4347594AAA1 Q37012017-66E6032C-9EC4-4B77-A661-42FC667D0497 Q37065532-67713E30-1B66-470F-934F-BCC465EA5E70 Q37079828-4E88EF14-361D-4E4D-827A-77CF4228E393 Q37142044-06D8C978-CD7B-4E2E-AE22-5651C4609938 Q37179467-AF61CBE5-E45F-4672-BE98-CF7C18129B6F Q37242253-D8B7FA7A-D28F-4F79-A63C-19015A2CC5AB Q37277818-66B31B6C-D605-41E5-92AE-29EB1F111A6A Q37329149-B21BA1A3-1243-4A69-80D3-052269A49F96 Q37362740-C6F1CCBA-6D7A-4A59-B6E0-BBC88D712D1F Q37400355-099E02AB-40ED-43A4-9913-51F6A45291BA

P2860

Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

http://www.wikidata.org/entity/Q40839780

description

2000 nî lūn-bûn

@nan

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

2000年學術文章

@zh

2000年學術文章

@zh-hant

name

Activation of human peroxisome ...... PAR) subtypes by pioglitazone.

@en

type

label

Activation of human peroxisome ...... PAR) subtypes by pioglitazone.

@en

prefLabel

Activation of human peroxisome ...... PAR) subtypes by pioglitazone.

@en

P1433

Q40839780-CCAF12B8-BFFF-4327-9924-205710B4D2E3

P1476

Q40839780-E3F48118-2101-4E9B-A0B4-94D41E0C679B

P2093

Q40839780-01A5A7FE-DD59-4D1A-8DA1-59792D8F219E

Q40839780-1FE0A25A-C48D-43D2-8611-F2F4BC1A6DE2

Q40839780-202BED0C-07BB-45A9-B846-D9895BF611D6

Q40839780-8B0FDBF9-B625-42B3-AD03-7CC534B38011

Q40839780-99195B23-5682-4219-8C72-6BCFF511FD44

Q40839780-AD02E991-BD62-412E-B59F-4FFC34360659

Q40839780-C4F80F50-3C12-4A92-9B65-4EC8827D7709

P304

Q40839780-B0DE7A92-4B12-4581-9C83-75691784DC2F

P31

Q40839780-DD7B6E4D-6703-487B-8FC7-5A538AB558DA

P356

Q40839780-F3D93066-5B30-42A6-A82E-B6375E679B49

P433

Q40839780-D955BFC3-9006-4881-9205-7E80F1473AFD

P478

Q40839780-286A5BD6-8420-4607-AF86-63FA9813A4C8

P577

Q40839780-E3A051A7-D425-4EB6-B48E-934E89877CC4

P698

Q40839780-24AA6803-C35A-4A1A-BAD4-A796F0EB59CF

P356

P1433

Biochemical and Biophysical Research Communications

P1476

Activation of human peroxisome ...... PAR) subtypes by pioglitazone.

@en

P2093

Kimura H

http://www.w3.org/2001/XMLSchema#string

Momose Y

http://www.w3.org/2001/XMLSchema#string

Moriyama S

http://www.w3.org/2001/XMLSchema#string

Odaka H

http://www.w3.org/2001/XMLSchema#string

Sakamoto J

http://www.w3.org/2001/XMLSchema#string

Sawada H

http://www.w3.org/2001/XMLSchema#string

Sugiyama Y

http://www.w3.org/2001/XMLSchema#string

P304

704-711

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1006/BBRC.2000.3868

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

278

http://www.w3.org/2001/XMLSchema#string

P577

2000-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11095972

http://www.w3.org/2001/XMLSchema#string